|
|
Taiwan Academic Institutional Repository >
Browse by Title
|
Showing items 655206-655215 of 2348617 (234862 Page(s) Totally)
<< < 65516 65517 65518 65519 65520 65521 65522 65523 65524 65525 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 國立臺灣大學 |
2016 |
Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study
|
Zhu, A.; Knox, J.; Kudo, M.; Chan, S.; Finn, R.; Siegel, A.; Ma, J.; Watson, P. A.; Cheng, A-L.; 鄭安理 |
| 臺大學術典藏 |
2020-10-22T07:41:44Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
WEI-LI CHEN; Liu J.-H.; Yao M.; Hsiao C.-C.; Hsiao C.-C.;Yao M.;Liu J.-H.;Wei-Li Chen |
| 臺大學術典藏 |
2021-07-22T03:35:56Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Hsiao C.-C.; Yao M.; LIU JIA-HAU; Chen W.-L. |
| 臺大學術典藏 |
2021-01-05T03:34:30Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Chen W.-L.; Liu J.-H.; MING YAO; Hsiao C.-C. |
| 臺大學術典藏 |
2022-04-25T07:36:14Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Hsiao C.-C.; Yao M.; JIA-HAU LIU; Chen W.-L. |
| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
Showing items 655206-655215 of 2348617 (234862 Page(s) Totally)
<< < 65516 65517 65518 65519 65520 65521 65522 65523 65524 65525 > >>
View [10|25|50] records per page
|
